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acroautophagy is a key pathway for the clear-
ance of aggregate-prone cytosolic proteins.
Currently, the only suitable pharmacologic strat-
egy for up-regulating autophagy in mammalian cells is to
use rapamycin, which inhibits the mammalian target of
rapamycin  (mTOR), a negative regulator of autophagy.
Here we describe a novel mTOR-independent pathway
that regulates autophagy. We show that lithium induces
autophagy, and thereby, enhances the clearance of au-
tophagy substrates, like mutant huntingtin and 
 
 
 
-synucleins.
This effect is not mediated by glycogen synthase kinase 3
 
 
M
 
inhibition. The autophagy-enhancing properties of lithium
were mediated by inhibition of inositol monophosphatase
and led to free inositol depletion. This, in turn, decreased
myo-inositol-1,4,5-triphosphate (IP
 
3
 
) levels. Our data sug-
gest that the autophagy effect is mediated at the level of
(or downstream of) lowered IP
 
3
 
, because it was abrogated
by pharmacologic treatments that increased IP
 
3
 
. This novel
pharmacologic strategy for autophagy induction is inde-
pendent of mTOR, and may help treatment of neurode-
generative diseases, like Huntington’s disease, where the
toxic protein is an autophagy substrate.
 
Introduction
 
The ubiquitin–proteasome and autophagy–lysosomal pathways
are the two major routes for protein and organelle clearance in
eukaryotic cells. Proteasomes predominantly degrade short-
lived nuclear and cytosolic proteins. The bulk degradation of
cytoplasmic proteins or organelles is mediated largely by mac-
roautophagy, generally referred to as autophagy. It involves the
formation of double-membrane structures, called autophago-
somes, which fuse with lysosomes to form autolysosomes.
Autophagy substrates generally have long half-lives (Klionsky
and Emr, 2000).
Autophagy also can help cells clear the toxic, long-lived,
aggregate-prone proteins, like mutant huntingtin and A53T,
and A30P mutants of 
 
 
 
-synuclein (Ravikumar et al., 2002;
Webb et al., 2003), which cause neurodegenerative disorders,
such as Huntington’s disease (HD) (Rubinsztein, 2002) and
forms of Parkinson’s disease (PD) (Polymeropoulos et al.,
1997; Kruger et al., 1998), respectively. Induction of autoph-
agy reduced the levels of mutant huntingtin and protected
against its toxicity in cells (Ravikumar et al., 2002), and in
transgenic 
 
Drosophila
 
 and mouse models of HD (Ravikumar et
al., 2004). The only suitable pharmacologic strategy for up-reg-
ulating autophagy in mammalian brains is to use rapamycin, or
its analogs, that inhibit the mammalian target of rapamycin
(mTOR), a negative regulator of autophagy.
HD is an autosomal-dominant neurodegenerative disorder
that is caused by a CAG trinucleotide repeat expansion in the
huntingtin gene (Huntington’s Disease Collaborative Research
Group, 1993), which results in an expansion of the poly-
glutamine tract in the NH
 
2
 
 terminus of the huntingtin protein.
Asymptomatic individuals have 
 
 
 
35 CAG repeats, whereas HD
is caused by 
 
 
 
36 repeats (Rubinsztein et al., 1996). Mutant hun-
tingtin accumulates in intraneuronal aggregates (also called in-
clusions). Huntingtin is cleaved to form NH
 
2
 
-terminal fragments
that consist of the first 100–150 residues containing the ex-
panded polyglutamine tract, which are believed to be the toxic
species found in the aggregates. Thus, HD pathogenesis fre-
quently is modeled with exon 1 fragments that contain expanded
polyglutamine repeats, which cause aggregate formation and
toxicity in cell models and in vivo (Rubinsztein, 2002).
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PD is another condition that is associated with aggre-
gate formation. The intraneuronal Lewy body aggregates that
characterize PD have the protein 
 
 
 
-synuclein as a major
component. The A53T and A30P point mutations in 
 
 
 
-synu-
clein cause autosomal dominant forms of Parkinson’s disease
(Polymeropoulos et al., 1997; Kruger et al., 1998). Unlike
wild-type 
 
 
 
-synuclein, the clearance of these mutant forms is
retarded when autophagy is inhibited (Webb et al., 2003; Cu-
ervo et al., 2004). Although these forms of 
 
 
 
-synuclein ag-
gregate in vivo, we do not observe overt aggregation in our
cell lines (Webb et al., 2003). Furthermore, unlike wild-type
 
 
 
-synuclein, these mutant forms are not cleared by the chap-
erone-mediated autophagy pathway (Cuervo et al., 2004),
which is distinct from macroautophagy (called “autophagy”
in this paper). Hence, we have used these mutations as model
autophagy substrates.
We showed previously that lithium is protective in HD
cell models, because it reduced mutant huntingtin aggregates
and cell death (Carmichael et al., 2002). Lithium is used as a
mood-stabilizing treatment of bipolar disorder, which is char-
acterized by recurrent fluctuations in mood (Manji and Lenox,
1998). Although lithium has been used for decades for bipolar
and unipolar affective disorders, the mechanism that underlies
its therapeutic action is not understood fully. Here we describe
a novel role for lithium as an inducer of autophagy. Lithium
facilitated the clearance of known autophagy substrates, like
mutant huntingtin and A53T, and A30P mutants of 
 
 
 
-synuclein.
Lithium induced autophagy by inhibiting inositol monophos-
phatase (IMPase), which led to reduced free inositol and myo-
inositol-1,4,5-triphosphate (IP
 
3
 
) levels. This represents a novel
pathway for regulation of mammalian autophagy.
 
Results
 
Lithium facilitates clearance of mutant 
huntingtin and 
 
 
 
-synuclein
 
The possibility that lithium regulates the clearance of certain
proteins was suggested by our observations that it significantly
reduced aggregation and cell death in COS-7 (nonneuronal) and
SK-N-SH (neural precursor) cells (Carmichael et al., 2002)
(Fig. 1, A and B), that were caused by truncated forms of mu-
tant huntingtin. In our earlier experiments, we showed protec-
tive effects with concentrations from 2.5–5 mM (Carmichael et
al., 2002). Here we used 10 mM, because this concentration was
used in the seminal paper from Harwood and colleagues that
demonstrated that lithium, carbamazepine, and valproate de-
creased inositol levels (Williams et al., 2002). Expression levels
of EGFP-tagged huntingtin exon 1 with 74 polyglutamine re-
peats (EGFP-HDQ74) correlate with aggregate formation (the
proportion of transfected cells with aggregates) in such cell
models (Narain et al., 1999; Ravikumar et al., 2002). We previ-
ously showed that EGFP-HDQ74 is cleared by autophagy. This
is not the result of protein overexpression or the EGFP tag, be-
cause blocking autophagy had no obvious effect on the levels of
isolated EGFP, but increased levels of HA-tagged HDQ74 as
well as EGFP-HDQ74 (Ravikumar et al., 2002).
To investigate if the reduced aggregation of the hunting-
tin construct was due to enhanced clearance, we used a sta-
ble doxycycline-inducible PC12 cell line expressing EGFP-
HDQ74, where transgene expression is first induced by adding
doxycycline and then switched off by removing doxycycline
from the medium. If one follows transgene expression levels at
various times after switching off expression after an initial in-
Figure 1. Lithium facilitates clearance of mutant huntingtin
fragment. COS-7 (A) and SK-N-SH (B) cells transfected
with pEGFP-HDQ74 were treated with or without 10 mM
LiCl or 10 mM NaCl for 48 h. The effects of treatment on
the percentage of EGFP-HDQ74-positive cells with aggre-
gates or apoptotic morphology (cell death) were ex-
pressed as odds ratios. Stable inducible PC12 cells ex-
pressing EGFP-HDQ74 were induced with doxycycline
for 8 h, then transgene expression was switched off for
120 h (by removing doxycycline), with ( ) or without ( )
10 mM LiCl (C) or 10 mM NaCl (D). Clearance of solu-
ble EGFP-HDQ74 was analyzed by immunoblotting with
antibody against EGFP (i). Densitometry analysis of solu-
ble EGFP-HDQ74 relative to actin (ii) was done from
three independent experiments. Untreated cells were
termed “120 h off”. (E) The percentage of EGFP-positive
cells with aggregates in stable PC12 cells expressing
EGFP-HDQ74, induced and treated for 120 h as in Fig. 1,
C and D with 10 mM LiCl or 10 mM NaCl, were as-
sessed and expressed as odds ratio compared with con-
trol condition (120 h off). (F) Clearance of aggregated
and soluble EGFP-HDQ74 in stable PC12 cells as in Fig.
1 C, treated with ( ) or without ( ) 10 mM LiCl for 120 h,
was analyzed by immunoblotting with antibody against
EGFP. The aggregated EGFP-HDQ74 is seen in the stack-
ing gel. ***, P   0.001; NS, non-significant. 
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duction period, one can assess if specific agents alter the clear-
ance of the transgene product, as the amount of transgene prod-
uct decays when synthesis is stopped (Ravikumar et al., 2002).
Using this paradigm, we observed that lithium (but not NaCl)
significantly enhanced clearance of soluble EGFP-HDQ74
(Fig. 1, C and D) and reduced aggregates at 120 h (Fig. 1 E;
Fig. S1 A, available at http://www.jcb.org/cgi/content/full/
jcb.200504035/DC1) and 170 h (Fig. S1, B and C). Further-
more, at 120 h, lithium enhanced the clearance of the insoluble
mutant huntingtin that gets retarded in the stacking gel (Fig. 1 F).
However, because this is probably less reliable quantified than
scoring aggregates, we have used aggregate counts (e.g., Fig. 1 E)
as a measure of insoluble huntingtin clearance. The clearance
of aggregates is likely to be a consequence of removal of aggre-
gate precursors (soluble and oligomeric species), rather than big
aggregates that are much larger than typical autophagosomes,
and will also not be able to enter the proteasome barrel (Ravi-
kumar et al., 2004).
Furthermore, we assessed clearance of A53T and A30P
 
 
 
-synuclein mutants. After induction of stable inducible PC12
cell lines (Webb et al., 2003) and subsequent removal of doxy-
cycline, lithium treatment for 24 h significantly enhanced the
clearance of A53T (Fig. 2 A) and A30P (Fig. 2 B) 
 
 
 
-synuclein
mutants; no effect was observed with NaCl (Fig. 2 C).
 
Lithium induces autophagy to enhance 
clearance of mutant proteins
 
We assessed if lithium induced autophagy, because the clear-
ance of EGFP-HDQ74 and the A53T and A30P 
 
 
 
-synuclein
mutants are strongly dependent on this pathway (Ravikumar et
al., 2002, 2004; Webb et al., 2003). The microtubule-associ-
ated protein 1 light chain 3 (LC3), a homologue of Apg8p that
is essential for autophagy in yeast, is processed posttranslation-
ally into LC3-I, which is cytosolic. LC3-I is converted to LC3-
II, which associates with autophagosome membranes (Kabeya
et al., 2000). Because LC3 specifically associates with auto-
phagosomes, the numbers of LC3-positive vesicles reflect au-
tophagosome number (Kabeya et al., 2000), which is a specific
and sensitive assay that has been used widely (for review see
Mizushima, 2004). Lithium increased the number of LC3-
positive autophagic vesicles in COS-7 cells, like rapamycin
(Fig. 2 D), and increased the levels of LC3-II (Fig. 2 E). The
modest increase in LC3-II is similar to that observed when au-
tophagy was induced (Kabeya et al., 2000). We next transfected
COS-7 or HeLa cells with LC3 fused to EGFP (EGFP-LC3).
EGFP-LC3 localizes only to autophagic membranes but not
other membrane structures (Kabeya et al., 2000). Because
EGFP-LC3 overexpression does not affect autophagic activity,
numbers of EGFP-LC3 vesicles have been used frequently to
Figure 2. Lithium induces autophagy. Stable
inducible PC12 cell lines expressing A53T (A)
or A30P (B)  -synuclein mutants were induced
with doxycycline for 48 h; expression of trans-
gene was switched off for 24 h, with ( ) or
without ( ) 10 mM LiCl. (i) Clearance of mutant
 -synucleins was analyzed by immunoblotting
with antibody against HA. (ii) Densitometry
analysis of mutant  -synuclein relative to actin
was done from three independent experi-
ments. The untreated cells were termed “24 h
off.” (C) Clearance of A53T (i) and A30P (ii)
 -synuclein mutants in stable PC12 cells as in
Fig. 2, A and B, treated with ( ) or without
( ) 10 mM NaCl for 24 h, was analyzed by
immunoblotting with antibody against HA. (D)
COS-7 cells treated with or without 10 mM
LiCl or 0.2  M rapamycin (Rap) for 24 h,
were analyzed by immunofluorescence with
antibody against LC3 using a confocal micro-
scope. Bar, 20  m. (E) COS-7 cells, treated
as in Fig. 2 D, were analyzed by immunoblot-
ting (i) with antibody against LC3. Densitome-
try analysis of LC3-II levels relative to actin (ii)
was done from three independent experi-
ments. (F) COS-7 cells were treated with or
without 10 mM LiCl or 0.2  M rapamycin
(Rap) for 120 h, and mitochondrial load was
assessed by immunoblotting with antibody to
complex IV. (G) The percentage of EGFP-
HDQ74–positive cells with aggregates in
COS-7 cells treated with ( ) or without ( ) 10
mM 3-MA, 10 mM LiCl, or both for 48 h as in
Fig. 1 A, were expressed as odds ratio. (H)
Clearance of A53T  -synuclein in stable in-
ducible PC12 cells as in Fig. 2 A, treated with
( ) or without ( ) 10 mM 3-MA, 10 mM LiCl,
or both for 24 h, was analyzed by immuno-
blotting with antibody against HA. *, P  
0.05; **, P   0.01; ***, P   0.001; NS,
non-significant.  
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assess autophagic activity (Mizushima et al., 2004). A signifi-
cantly greater proportion of lithium-treated cells expressing
EGFP-LC3 had overt vesicle formation compared with un-
treated cells, even at a therapeutically-relevant dose (1 mM)
(Fig. S2, A and B; available at http://www.jcb.org/cgi/content/
full/jcb.200504035/DC1). Furthermore, we assessed the mito-
chondrial load in cells that were treated with lithium by immu-
noblotting for mitochondrial complex IV, because mitochon-
dria are endogenous autophagy substrates (Klionsky and Emr,
2000). After 120 h of treatment with lithium, complex IV lev-
els were reduced in COS-7 cells (Fig. 2 F). Autophagy induc-
tion with rapamycin also reduced levels of complex IV (Fig. 2 F),
and complex IV accumulates when autophagy was inhibited
(e.g., with 3-methyl adenine) (unpublished data).
If lithium facilitates clearance of EGFP-HDQ74 and mu-
tant 
 
 
 
-synucleins through autophagy, then it should be blocked
by the autophagy inhibitor, 3-methyladenine (3-MA). 3-MA
increased EGFP-HDQ74 aggregate formation in COS-7 cells
(Ravikumar et al., 2002) (Fig. 2 G; Fig. S2 C), and delayed
clearance of A53T 
 
 
 
-synuclein (Webb et al., 2003) (Fig. 2 H).
Furthermore, 3-MA completely abolished the effect of lithium
in reducing EGFP-HDQ74 aggregation (Fig. 2 G; Fig. S2 C),
or promoting A53T 
 
 
 
-synuclein clearance (Fig. 2 H). Thus,
lithium induces autophagy and enhances the clearance of
known autophagy substrates, such as EGFP-HDQ74 and mutant
 
 
 
-synucleins.
 
Lithium enhances clearance of mutant 
proteins by inositol monophosphatase 
inhibition
 
Lithium inhibits a number of enzymes, including glycogen syn-
thase kinase-3
 
 
 
 (GSK-3
 
 
 
) and IMPase (Gould et al., 2002;
Coyle and Duman, 2003). To test if either of these enzymes was
involved in autophagy regulation, we used specific inhibitors
of GSK-3
 
 
 
 (SB216763) (Coghlan et al., 2000) and IMPase
(L-690,330) (Atack et al., 1993) (Fig. S3; available at http://
www.jcb.org/cgi/content/full/jcb.200504035/DC1). L-690,330
reduced aggregation and cell death that were caused by EGFP-
HDQ74 in COS-7 and SK-N-SH cells, whereas SB216763 in-
creased EGFP-HDQ74 aggregates but reduced cell death, which
was consistent with our earlier findings (Carmichael et al.,
2002) (Fig. 3, A and B). The idea that IMPase was involved in
autophagy regulation was supported further because L-690,330
facilitated clearance of soluble EGFP-HDQ74 (Fig. 3 C) and the
mutant 
 
 
 
-synucleins (Fig. 3 D), whereas SB216763 had no ef-
fect on clearance of soluble EGFP-HDQ74 (Fig. 3 E) and
seemed to slow clearance of mutant 
 
 
 
-synucleins in stable PC12
cell lines (Fig. 3 F). Because SB216763, if anything, slows
clearance of these substrates, the enhanced clearance of mutant
huntingtin and 
 
 
 
-synucleins that is mediated by lithium cannot
be due to the drug inhibiting GSK-3
 
 
 
.
 
Lithium induces autophagy by inhibiting 
IMPase
 
We tested if the enhanced clearance of these proteins mediated
by L-690,330 was by autophagy or the proteasomal route, using
inhibitors of autophagy (3-MA) and the proteasome (lactacystin).
Both of these inhibitors reduced clearance of A53T 
 
 
 
-synuclein
in the PC12 stable line (Fig. 4, A and B), and increased EGFP-
HDQ74 aggregates in COS-7 cells (Fig. 4, C and D); this was
consistent with our previous observations that these proteins are
cleared by autophagy and the proteasome (Ravikumar et al.,
2002; Webb et al., 2003). When autophagy was inhibited by
3-MA, L-690,330 could not facilitate clearance of A53T 
 
 
 
-synu-
clein or reduce EGFP-HDQ74 aggregates (Fig. 4, A and C).
However, cells that were treated with the proteasome inhibitor,
lactacystin, and L-690,330 had enhanced clearance of A53T
 
 
 
-synuclein and significantly reduced EGFP-HDQ74 aggregates,
compared with cells that were treated with lactacystin alone
(Fig. 4, B and D). This suggested that the enhanced clearance of
these proteins was mediated by IMPase inhibition by way of a
nonproteasomal route. We confirmed that L-690,330 enhanced
clearance of these proteins through the autophagic route by
Figure 3. Lithium accelerates clearance of mutant huntingtin fragment by
inositol monophosphatase inhibition. The percentage of EGFP-HDQ74–pos-
itive cells with aggregates and cell death in COS-7 (A) and SK-N-SH (B)
cells as in Fig. 1, A and B, treated with or without 10  M SB216763 or
100  M L-690,330 for 48 h, were expressed as odds ratios. (C) Clearance
of soluble EGFP-HDQ74 in stable inducible PC12 cell lines as in Fig. 1 C,
treated with ( ) or without ( ) 100  M L-690,330 for 170 h, was ana-
lyzed by immunoblotting with antibody against EGFP (i) and densitometry
(ii). (D) Clearance of A53T (i) and A30P (ii)  -synucleins in stable inducible
PC12 cells as in Fig. 2, A and B, treated with ( ) or without ( ) 100  M
L-690,330 for 24 h, was analyzed by immunoblotting with antibody against
HA. (E) Clearance of soluble EGFP-HDQ74 in stable inducible PC12 cell
lines as in Fig. 1 C, treated with ( ) or without ( ) 10  M SB216763 for
170 h, was analyzed by immunoblotting with antibody against EGFP (i) and
densitometry (ii). (F) Clearance of A53T (i) and A30P (ii)  -synucleins in sta-
ble inducible PC12 cells as in Fig. 2, A and B, treated with ( ) or without
( ) 10  M SB216763 for 24 h, was analyzed by immunoblotting with anti-
body against HA. ***, P   0.001; NS, non-significant. 
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showing more LC3-stained autophagic vesicles in COS-7 cells
after L-690,330 treatment (Fig. 4 E). Furthermore, L-690,330
also decreased mitochondrial load as judged by complex IV
(Fig. 4 F) and cytochrome 
 
c
 
 (not depicted) levels in COS-7
cells. Accordingly, the IMPase inhibitory activity of lithium can
account for its induction of autophagy.
We confirmed that lithium and L-690,330 were inhibiting
IMPase in our experimental conditions, because they increased
levels of inositol mono- and bis-phosphate (IP
 
1-2
 
) (Fig. 4 G) and
decreased IP
 
3
 
 levels (Fig. 4 H), a consequence of reduced free
inositol (Berridge et al., 1989). Lithium significantly reduced IP
 
3
 
levels at time points from 1 min to 24 h (Fig. S4 A; available at
http://www.jcb.org/cgi/content/full/jcb.200504035/DC1).
 
Mood-stabilizing drugs facilitate 
clearance of mutant proteins
 
Inositol depletion is a common mechanism for mood stabiliz-
ing drugs like lithium, carbamazepine (CBZ), and valproic acid
(VPA) (Williams et al., 2002). Consistent with a role for inosi-
tol depletion in autophagy regulation, CBZ significantly re-
duced EGFP-HDQ74 aggregates and attenuated polyglutamine
toxicity in COS-7 cells (Fig. 4 I), and enhanced clearance of
A30P 
 
 
 
-synuclein (Fig. 4 J). Similar results were seen with
VPA (unpublished data). Thus, drugs that can deplete intracel-
lular inositol may be of therapeutic value in HD and related
neurodegenerative diseases.
 
The effect of lithium on clearance of 
mutant proteins is regulated by IP
 
3
 
 levels
 
To determine the importance of inositol levels in autophagy
regulation, we tested if the effect of lithium on autophagy could
be overcome by the addition of extracellular inositol in the
form of myo-inositol (Williams et al., 2002). We also used an
inhibitor of prolyl oligopeptidase activity, called prolyl en-
dopeptidase inhibitor 2 (PEI), which elevates intracellular IP
 
3
 
and abolishes some other effects of lithium (Williams et al.,
1999) (Fig. S4 B). Lithium may deplete inositol by inhibiting
IMPase and by decreasing the transport of myo-inositol into
cells (Lubrich and van Calker, 1999). Accordingly, we pre-
treated cells with myo-inositol and PEI before adding lithium.
As predicted, myo-inositol and PEI pretreatment raised IP
 
3
 
 lev-
els in COS-7 cells that were treated with lithium, compared
with lithium treatment alone (Fig. 5 A). Myo-inositol and PEI
significantly reversed the protective effect of lithium on EGFP-
HDQ74–induced aggregation and cell death in COS-7 cells
(Fig. 5 B). (The failure of myo-inositol and PEI to reverse com-
pletely the lithium effect on EGFP-HDQ74 aggregation at 48 h
[Fig. 5 B]—despite their effects on IP
 
3
 
 levels at 5 min [Fig. 5 A]—
can be explained by the different timings of these observa-
tions.) These compounds also inhibited the effect of lithium on
the clearance of soluble EGFP-HDQ74 (Fig. 5 C) and A53T
 
 
 
-synuclein (Fig. 5 D) in stable PC12 cell lines.
Single treatments of myo-inositol or PEI, which each in-
creased intracellular IP
 
3
 
 (Fig. 5 E), increased EGFP-HDQ74
aggregates and cell death in COS-7 cells (Fig. 5 F) and signifi-
cantly inhibited the clearance of soluble EGFP-HDQ74 (Fig. 5,
G and H). We next tested whether myo-inositol or PEI inhib-
ited proteasome activity using HeLa cells stably expressing the
Ub
G76V-GFP reporter (Dantuma et al., 2000), a fluorescent-
specific proteasome substrate. Treatment with the proteasome
Figure 4. Lithium induces autophagy by inositol monophosphatase inhi-
bition. Clearance of A53T  -synuclein in stable inducible PC12 cells as in
Fig. 2 A, treated with ( ) or without ( ) 10 mM 3-MA, 100  M L-690,330,
or both (A), or 10  M lactacystin (Lact), 100  M L-690,330, or both (B) for
24 h, was analyzed by immunoblotting with antibody against HA. The
percentage of EGFP-HDQ74–positive cells with aggregates in COS-7
cells as in Fig. 1 A, treated with ( ) or without ( ) 10 mM 3-MA, 100  M
L-690,330, or both (C), or 10  M lactacystin (Lact), 100  M L-690,330,
or both (D) for 48 h, were expressed as odds ratio. (E) COS-7 cells treated
with ( ) or without ( ) 100  M L-690,330 for 24 h were analyzed by im-
munofluorescence with antibody against LC3 using a confocal microscope.
Bar, 20  m. (F) COS-7 cells were treated with or without 100  M L-690,330
for 170 h, and mitochondrial load was assessed by immunoblotting with
antibody to complex IV. (G) Levels of IP1-2 were measured in COS-7 cells
treated with 10 mM LiCl or 100  M L-690,330 for 24 h. (H) Levels of IP3
were measured in COS-7 cells treated with 2  M bradykinin, 10 mM LiCl,
or 100  M L-690,330 for 5 min. (I) The percentage of EGFP-HDQ74–posi-
tive cells with aggregates and cell death in COS-7 cells as in Fig. 1 A,
treated with or without 50  M CBZ for 48 h, were expressed as odds ra-
tios. (J) Clearance of A30P  -synuclein in stable inducible PC12 cells as
in Fig. 2 B, treated with ( ) or without ( ) 50  M CBZ for 24 h, was
analyzed by immunoblotting with antibody against HA. **, P   0.01;
***, P   0.001; NS, non-significant.JCB • VOLUME 170 • NUMBER 7 • 2005 1106
inhibitor, lactacystin, led to massive accumulation of the fluo-
rescent substrate, whereas myo-inositol or PEI had no effect on
its levels, compared with the untreated (control) cells (Fig. 5 I).
We showed above that lithium (which has IMPase inhibitory
activity) and an IMPase inhibitor reduced intracellular IP3 and
induced autophagy (Fig. 2, D–F; Fig. 4, E, F, and H). Because
increasing intracellular IP3 inhibited the clearance of mutant
huntingtin, these data suggest that lithium is inducing autoph-
agy by virtue of its IMPase inhibitory activity, acting at the
level of (or downstream of) lowered IP3.
Lithium and IMPase inhibitor induce 
autophagy independently of 
mTOR inhibition
We were interested if this novel means of pharmacologic regu-
lation of autophagy was independent of the known pathway
Figure 5. Lithium accelerates clearance of mutant huntingtin fragment by reducing free inositol and IP3 levels. (A) IP3 levels were measured in COS-7
cells treated for 5 min with or without 2  M bradykinin, 10 mM LiCl, or 10 mM LiCl pretreated for 5 min with 1 mM myo-inositol (Ins) or 24  M prolyl
endopeptidase inhibitor 2 (PEI). (B) The percentage of EGFP-HDQ74–positive cells with aggregates (i) and cell death (ii) in COS-7 cells as in Fig. 1 A,
either left untreated or treated with 10 mM LiCl with ( ) or without ( ) 1mM myo-inositol or 24  M PEI for 48 h, were expressed as odds ratios. (C) Clear-
ance of soluble EGFP-HDQ74 in stable PC12 cells as in Fig. 1 C, either left untreated or treated with 10 mM LiCl with ( ) or without ( ) 1 mM myo-inositol
or 24  M PEI for 120 h, was analyzed by immunoblotting with antibody against EGFP (i) and densitometry (ii). (D) Clearance of A53T  -synuclein in sta-
ble PC12 cells as in Fig. 2 A, either left untreated or treated with 10 mM LiCl with ( ) or without ( ) 1 mM myo-inositol or 24  M PEI for 24 h, was
analyzed by immunoblotting with antibody against HA. (E) IP3 levels were measured in COS-7 cells treated with or without 1 mM myo-inositol, 24  M PEI
or 0.2  M rapamycin (Rap) for 5 min. (F) The percentage of EGFP-HDQ74–positive cells with aggregates and cell death in COS-7 cells as in Fig. 1 A,
treated with or without 1 mM myo-inositol or 24  M PEI for 48 h, were expressed as odds ratios. Clearance of soluble EGFP-HDQ74 in stable PC12 cells
as in Fig. 1 C, treated with ( ) or without ( ) 1 mM myo-inositol (G) or 24  M PEI (H) for 120 h, was analyzed by immunoblotting with antibody against
EGFP (i) and densitometry (ii). (I) HeLa cells expressing Ub
G76V-GFP reporter, treated with or without 10  M lactacystin (Lact), 1 mM myo-inositol, or 24  M
PEI for 24 h, were analyzed by fluorescence microscopy. Bar, 20  m. *, P   0.05; **, P   0.01; ***, P   0.001; NS, non-significant; Ins, myo-inositol.LITHIUM INDUCES AUTOPHAGY • SARKAR ET AL. 1107
that is regulated negatively by mTOR. The activity of mTOR, a
protein kinase, can be inferred by the levels of phosphorylation
of its substrates, ribosomal S6 protein kinase (S6K1, also
known as p70S6K) and eukaryotic initiation factor 4E-binding
protein 1 (4E-BP1) at Thr389 and Thr37/46, respectively
(Fig. S5 A; available at http://www.jcb.org/cgi/content/full/
jcb.200504035/DC1), and the phosphorylation of the riboso-
mal S6 protein (S6P), a substrate of S6K1 (Schmelzle and Hall,
2000). Whereas rapamycin (a specific mTOR inhibitor) re-
duced phosphorylation of S6K1, S6P, and 4E-BP1 in COS-7
cells as expected, lithium or L-690,330 did not reduce their
phosphorylation (Fig. 6, A–D; Fig. S5 B), which suggests that
their effects are independent of mTOR inhibition.
Overexpression of the small G-protein rheb, which
greatly enhances mTOR signaling (Manning and Cantley,
2003), markedly increased EGFP-HDQ74 aggregates and cell
death in COS-7 cells (Ravikumar et al., 2004) (Fig. 6 E).
However, lithium or L-690,330 reduced EGFP-HDQ74 aggre-
gates and cell death in rheb-transfected cells (Fig. 6 F); this
Figure 6. Lithium and IMPase inhibitor do not impair mTOR signaling.
COS-7 cells treated with or without 10 mM LiCl, 0.2  M rapamycin (Rap),
or 100  M L-690,330 for 24 h, were analyzed for mTOR activity by immu-
noblotting for levels of phospho and total mTOR (A), ribosomal S6 protein
kinase (B), S6P (C), and 4E-BP1 (D). (E and F) COS-7 cells transfected with
pEGFP-HDQ74 along with empty vector (pCDNA3.1) or pRheb at 1:3 ratio
(E). The rheb-transfected cells were treated with or without 10 mM LiCl or
100  M L-690,330; the control represents untreated rheb-transfected cells
(F). The proportion of GFP-positive cells with aggregates or cell death were
assessed after 48 h and expressed as odds ratios. ***, P   0.001.
Figure 7. The ability of rapamycin to enhance clearance of mutant hun-
tingtin and  -synuclein is not impaired by increasing intracellular IP3.
(A) The percentage of EGFP-HDQ74-positive cells with aggregates (i) and
cell death (ii) in COS-7 cells as in Fig. 1 A, either left untreated or treated
with 0.2  M rapamycin with ( ) or without ( ) 1 mM myo-inositol (Ins) or
24  M PEI for 48 h, were expressed as odds ratios. (B) Clearance of solu-
ble EGFP-HDQ74 in stable PC12 cells as in Fig. 1 C, either left untreated or
treated with 0.2  M rapamycin with ( ) or without ( ) 1 mM myo-inositol or
24   M PEI for 120 h, was analyzed by immunoblotting with antibody
against EGFP (i) and densitometry (ii). (C) Clearance of A53T  -synuclein in
stable PC12 cells as in Fig. 2 A, either left untreated or treated with 0.2  M
rapamycin (Rap) with ( ) or without ( ) 1 mM myo-inositol or 24  M PEI
for 24 h, was analyzed by immunoblotting with antibody against HA.
*, P   0.05; ***, P   0.001; NS, non-significant; Ins, myo-inositol.JCB • VOLUME 170 • NUMBER 7 • 2005 1108
suggested that induction of autophagy by IMPase inhibition oc-
curs even when mTOR is activated.
The effect of IP3 on autophagy is unlikely to be a down-
stream consequence of mTOR inhibition, because rapamycin
had no effect on IP3 levels (Fig. 5 E). Furthermore, neither
myo-inositol nor PEI abolished the protective effect of rapam-
ycin on polyglutamine toxicity in COS-7 cells (Fig. 7 A), and
the increased clearance of soluble EGFP-HDQ74 and A53T
 -synuclein in stable PC12 cell lines (Fig. 7, B and C), in con-
trast to what we observed in the context of lithium. Therefore,
rapamycin and intracellular inositol seem to regulate autoph-
agy independently.
Inhibition of IMPase and mTOR additively 
enhance the clearance of mutant 
huntingtin and  -synuclein
We confirmed the prediction that lithium and rapamycin
should have additive effects in reducing EGFP-HDQ74 ag-
gregates and cell death in COS-7 cells (Fig. 8 A), compared
with the single treatments of lithium or rapamycin. Further-
more, lithium and rapamycin together facilitated greater
clearance of soluble EGFP-HDQ74 at 72 h (Fig. 8 B) and
A53T  -synuclein at 8 h (Fig. 8 C), compared with either
compound alone. To demonstrate this effect clearly we chose
early time points at which we do not observe obvious reduc-
tions of the levels of these proteins when the cells are treated
with either of the compounds alone. We have confirmed that
the rapamycin concentration that was used in these experi-
ments is close to saturating, because a further increase in the
rapamycin dose did not lead to more clearance of soluble
EGFP-HDQ74 (Fig. 8 D).
Consistent with the above observations, the combination
of L-690,330 and rapamycin had an enhanced protective ef-
fect on EGFP-HDQ74–mediated toxicity in COS-7 cells (Fig.
8 E), and facilitated greater clearance of soluble EGFP-
HDQ74 and A53T  -synuclein at early time points in stable
PC12 cell lines, compared with the individual treatments (Fig. 8,
F and G). Thus, two independent pathways of inducing au-
tophagy in mammalian cells have an additive effect, which is
reflected by the greater clearance of mutant proteins because
Figure 8. Induction of autophagy by two independent pathways has an additive effect on the clearance of mutant proteins. (A) The percentage of EGFP-
HDQ74–positive cells with aggregates (i) and cell death (ii) in COS-7 cells as in Fig. 1 A, treated with ( ) or without ( ) 10 mM LiCl, 0.2  M rapamycin
(Rap), or both for 48 h, were expressed as odds ratios. (B) Clearance of soluble EGFP-HDQ74 in stable PC12 cells as in Fig. 1 C, treated with ( ) or without
( ) 10 mM LiCl, 0.2  M rapamycin (Rap), or both for 72 h, was analyzed by immunoblotting with antibody against EGFP (i) and densitometry (ii). (C) Clear-
ance of A53T  -synuclein in stable PC12 cells as in Fig. 2 A, treated with ( ) or without ( ) 10 mM LiCl, 0.2  M rapamycin (Rap), or both for 8 h, was
analyzed by immunoblotting with antibody against HA. (D) Clearance of soluble EGFP-HDQ74 in stable PC12 cells as in Fig. 1 C, treated with ( ) or
without ( ) 0.1, 0.2, or 0.4  M rapamycin (Rap) for 72 h, was analyzed by immunoblotting with antibody against EGFP. (E) The percentage of EGFP-
HDQ74–positive cells with aggregates (i) and cell death (ii) in COS-7 cells as in Fig. 1 A, treated with ( ) or without ( ) 100  M L-690,330, 0.2  M rapa-
mycin (Rap), or both for 48 h, were expressed as odds ratios. (F) Clearance of soluble EGFP-HDQ74 in stable PC12 cells as in Fig. 1 C, treated with ( ) or
without ( ) 100  M L-690,330, 0.2  M rapamycin (Rap), or both for 72 h, was analyzed by immunoblotting with antibody against EGFP (i) and densi-
tometry (ii). (G) Clearance of A53T  -synuclein in stable PC12 cells as in Fig. 2 A, treated with ( ) or without ( ) 100  M L-690,330, 0.2  M rapamycin
(Rap), or both for 8 h, was analyzed by immunoblotting with antibody against HA. *, P   0.05; **, P   0.01; ***, P   0.001; NS, non-significant.LITHIUM INDUCES AUTOPHAGY • SARKAR ET AL. 1109
of simultaneous inhibition of mTOR and IMPase. This pro-
vides a new direction for combinatorial treatment of neuro-
degenerative disorders (e.g., HD) by enhancing autophagy by
two different routes.
Discussion
Lithium induces autophagy and enhances clearance of aggre-
gate-prone proteins, like mutant huntingtin and A53T, and
A30P mutants of  -synuclein in PC12, SK-N-SH (both neu-
ronal precursor cell lines), and COS-7 (nonneuronal) cells at
different time points (Fig. 1, A–C, E, and F; Fig. S1, A–C; Fig.
2, A, B, and D–F). These aggregate-prone proteins are distinct
confirmed autophagy substrates (Ravikumar et al., 2002; Webb
et al., 2003). This effect is not mediated by GSK-3  inhibition
(Fig. 3, A, B, E, and F), but is a consequence of IMPase inhibi-
tion, because an IMPase inhibitor, L-690,330, mediates similar
effects (Fig. 3, A–D; Fig. 4, E and F). This assertion was con-
firmed further by showing that the effects of lithium on the
clearance of EGFP-HDQ74 and mutant  -synuclein were abro-
gated with myo-inositol (Fig. 5, A–D), which increases intra-
cellular IP3 (Fig. 5 E). Furthermore, increasing the levels of IP3
by using PEI (Fig. 5 E) also abolished the effect of lithium on
the clearance of these mutant proteins (Fig. 5, A–D). Moreover,
free inositol (myo-inositol) inhibited clearance of autophagy
substrates (Fig. 5, F and G), which provided further support for
the role of IMPase as a regulator of autophagy, because this en-
zyme decreases the free inositol pool. Decreased free inositol
leads to decreased IP3 levels (Berridge et al., 1989). Our data
suggest that the autophagy effect is mediated at the level of (or
downstream of) lowered IP3, because it was abrogated by PEI
that increased intracellular levels of IP3 (Fig. 5, E, F, and H).
This represents a novel pathway of mammalian autophagy reg-
ulation. It will be extremely challenging to characterize the mo-
lecular mechanism whereby IP3 regulates autophagy, because
the machinery that regulates the rate of mammalian autophagy
under physiologic conditions is poorly understood. It is still not
clear how mTOR regulates mammalian autophagy.
Lithium is a major therapy for affective disorders (Manji
and Lenox, 1998). It takes 3–4 wk to stabilize mood, although
brain inositol levels in patients who have bipolar disorder are
reduced by lithium much sooner after treatment is initiated
(Moore et al., 1999). Because autophagy modulates the half-
lives of many long-lived proteins (Klionsky and Emr, 2000;
Ravikumar et al., 2002, 2004; Webb et al., 2003), it is tempting
to speculate that part of the therapeutic efficacy of lithium and
related drugs (e.g., CBZ and valproate) may be mediated by
clearance of very long half-life autophagy substrates that may
contribute to the disease. Steady-state levels of some long half-
life proteins could take weeks (many multiples of the half-life)
to change in a biologically significant way after the half-life
is shortened. This is a plausible explanation for why mood-
stabilizing drugs have acute effects on free inositol levels long
before they begin to mediate clinical effects. The different lag
times that are seen with various mood-stabilizing drugs may be
related to their pharmacokinetics—the fact that these drugs
may deplete intracellular inositol by different mechanisms
(Gould et al., 2002; Ju et al., 2004; Shaltiel et al., 2004) and/or
effects on other target enzymes that are unrelated to autophagy.
This speculative model does not mean necessarily that abnor-
mal protein degradation is a feature of affective disorders. It is
tempting to speculate whether trials of rapamycin or related au-
tophagy-inducing drugs may be worthwhile for mood disor-
ders, given the lack of understanding of their biology and the
enormous patient need.
Although the inositol depletion hypothesis may be one of
the most widely accepted hypotheses for lithium’s actions in
bipolar affective disorder (Silverstone et al., 2005), it remains
controversial. In rodents, lithium (and valproate) reduces myo-
inositol levels and increases IP1 concentrations in the brain
(Silverstone et al., 2005). Although the studies in humans have
been more difficult to interpret, this may be due, in part, to
technical limitations of magnetic resonance spectroscopy meth-
ods in humans, and sample size and clinical heterogeneity is-
sues (for review see Silverstone et al., 2005). Nevertheless, the
meta-analysis of data from manic and depressed studies gener-
ally is consistent with the inositol depletion hypothesis of lith-
ium action in these disorders (Silverstone et al., 2005). It is
clearly outside the realm of this study to resolve the contro-
versy of the inositol depletion hypothesis for lithium. Note also
that lithium can reduce inositol levels by two mechanisms. The
most commonly considered is by inhibition on inositol mono-
phosphatase. However, lithium also inhibits inositol uptake
into cells (Lubrich and van Calker, 1999). We performed most
studies using 10 mM lithium, following the precedent of Wil-
liams et al. (1999). Although this is higher than the desired
concentration in humans, we were able to show that the autoph-
agy effects at this dose were mediated specifically by inositol
depletion, because they were attenuated by myo-inositol and
prolyl endopeptidase inhibition. We previously showed that 2.5
mM lithium reduced polyglutamine aggregation and toxicity in
cell models (Carmichael et al., 2002). Furthermore, 1 mM lith-
ium (approximating the therapeutic levels in humans [Camus et
al., 2003]) induces autophagy (Fig. S2, A and B). Even if lith-
ium turns out to be not very effective at inducing autophagy in
humans, similar effects may be achieved with other drugs that
reduce inositol levels, like valproate or CBZ (Williams et al.,
2002) (Fig. 4, I and J; not depicted).
These issues do not detract from our fundamental cell bi-
ologic elucidation of a novel mTOR-independent autophagy
regulatory pathway. This may be of potential value in neurode-
generative diseases that are caused by aggregate-prone pro-
teins, such as HD (Ravikumar et al., 2004). Some benefit was
reported with lithium in a mouse model of HD (Wood and
Morton, 2003). Combination therapy with more moderate IMP-
ase and mTOR inhibition may be safer for long-term treat-
ment than using doses of either inhibitor that result in more
severe perturbation of a single pathway.
Materials and methods
Plasmids
HD gene exon 1 fragment with 74 polyglutamine repeats (Q74) in pEGFP-
C1 (CLONTECH Laboratories, Inc.) was described and characterized pre-
viously (Narain et al., 1999). EGFP-LC3 (gift from T. Yoshimori, NationalJCB • VOLUME 170 • NUMBER 7 • 2005 1110
Institute of Genetics, Mishima, Shizouka, Japan) and rheb (gift from K.L.
Guan, University of Michigan, Ann Arbor, MI) constructs were obtained.
Mammalian cell culture and transfection
African green monkey kidney cells (COS-7) and human neuroblastoma
cells (SK-N-SH) were maintained in DME (Sigma-Aldrich) supplemented
with 10% FBS (Sigma-Aldrich), 100 U/ml penicillin/streptomycin, and 2
mM L-glutamine (Sigma-Aldrich) at 37 C, 5% CO2. Cells were plated in
six-well dishes at a density of 10
5 cells per well for 24 h, and transfected
with pEGFP-HDQ74 using LipofectAMINE reagent for COS-7 cells and
LipofectAMINE PLUS reagent for SK-N-SH according to the manufacturer’s
protocol (Invitrogen). Transfection mixture was replaced after 4 h incuba-
tion at 37 C by various compounds, such as 10 mM LiCl, 0.2  M rapa-
mycin, 10 mM 3-MA, 10  M lactacystin, 50  M CBZ, 1 mM myo-inositol
(all from Sigma-Aldrich), 10 mM NaCl (BDH), 10  M SB216763 (Tocris),
100  M L-690,330 (Tocris), or 24  M prolyl endopeptidase inhibitor 2
(Z-PP-CHO, Calbiochem). Transfected cells were fixed with 4% parafor-
maldehyde (Sigma-Aldrich) after 48 h and mounted in DAPI (3 mg/ml;
Sigma-Aldrich) over coverslips on glass slides and analyzed for aggrega-
tion and cell death. For immunoblotting, cells were plated at a density of
3   10
5 cells per well. HeLa cells stably expressing Ub
G76V-GFP reporter
(gift from N.P. Dantuma, Karolinska Institutet, Stockholm, Sweden) were
grown in similar media used for growing COS-7 cells, which is supple-
mented with 0.5 mg/ml G418.
Inducible PC12 stable cell lines expressing EGFP-tagged exon 1 of
HD gene (EGFP-HDQ74) (Wyttenbach et al., 2001) and HA-tagged A53T
and  -synuclein mutants (Webb et al., 2003), were maintained at 75
 g/ml hygromycin B (Calbiochem) in standard DME with 10% horse se-
rum (Sigma-Aldrich), 5% FBS, 100 U/ml penicillin/streptomycin, 2 mM
L-glutamine, and 100  g/ml G418 (GIBCO BRL) at 37 C, 10% CO2.
Quantification of aggregate formation and cell death
 200 EGFP-positive cells were counted for proportion of cells with aggre-
gates, as described previously (Narain et al., 1999). Nuclei were stained
with DAPI; those that showed apoptotic morphology (fragmentation or
pyknosis) were considered abnormal. These criteria are specific for cell
death, and correlate highly with propidium iodide staining in live cells
(Wyttenbach et al., 2002). Analysis was performed using a Nikon Eclipse
E600 fluorescence microscope (plan-apo 60 /1.4 oil immersion lens at
room temperature); the observer was blinded to identity of slides. Slides
were coded and the code was broken after completion of the experiment.
All experiments were done in triplicate at least twice. Images were ac-
quired with a Nikon Digital Camera DXM1200 using Nikon Eclipse E600
fluorescence microscope (40  plan-fluor 40x/0.75 lens or plan-apo
60 /1.4 oil immersion lens at room temperature). Acquisition software
was Nikon ACT-1 version 2.12; Adobe Photoshop 6.0 (Adobe Systems,
Inc.) was used for subsequent image processing.
Clearance of mutant huntingtin and  -synucleins
Stable inducible PC12 cell lines expressing EGFP-HDQ74, or A53T or
A30P  -synuclein mutants, were plated at 3   10
5 per well in six-well
dishes and induced with 1  g/ml doxycycline (Sigma-Aldrich) for 8 h and
48 h, respectively. Expression of transgenes was switched off by removing
doxycycline from the medium (Ravikumar et al., 2002; Webb et al.,
2003); cells were treated with or without various compounds for 120 h for
EGFP-HDQ74 clearance and 24 h for mutant  -synuclein clearance. For
additive effect of LiCl or L-690,330 with rapamycin, treatment was done
for 72 h for EGFP-HDQ74 clearance and 8 h for mutant  -synuclein clear-
ance. The medium with various compounds was changed every 24 h.
Cells were fixed and mounted in DAPI, or processed for immunoblotting
analysis with EGFP for soluble EGFP-HDQ74 clearance or HA for mutant
 -synuclein clearance.
Western blot analysis
Cell pellets were lysed on ice in Laemmli buffer (62.5 mM Tris-HCl pH 6.8,
5%  -mercaptoethanol, 10% glycerol, and 0.01% bromophenol blue) for
30 min in the presence of protease inhibitors (Roche Diagnostics). Samples
were subjected to SDS-PAGE, and proteins were transferred to nitrocellu-
lose membrane (GE Healthcare). Primary antibodies used include anti-EGFP
(8362–1, CLONTECH Laboratories, Inc.), anti-HA (12CA5, Covance), anti-
mTOR (2972), anti–phospho-mTOR (Ser2448) (2971), anti-p70 S6 ki-
nase (9202), anti–phospho-p70 S6 kinase (Thr389) (9206), anti–4E-BP1
(9452), anti–phospho-4E-BP1 (Thr37/46) (9459), anti-S6 ribosomal pro-
tein (2212), and anti–phospho-S6 ribosomal protein (Ser235/236)
(2211), all from Cell Signaling Technology; anti-complex IV subunit IV
(A-21348, Molecular Probes), anti-LC3 (gift from T. Yoshimori), anti-actin
(A2066, Sigma-Aldrich), and anti-tubulin (clone DM 1A, Sigma-Aldrich).
Blots were probed with anti–mouse or anti–rabbit IgG-HRP (GE Healthcare)
and visualized using ECL or ECL Plus detection kit (GE Healthcare).
Immunocytochemistry
COS-7 cells were fixed with 4% paraformaldehyde. Primary antibodies in-
cluded anti-LC3 (gift from T. Yoshimori, National Institute of Genetics, Japan)
and anti–phospho-S6 ribosomal protein (Ser235/236) (2211, Cell Sig-
naling Technology). Standard fluorescence method was used for detec-
tion; secondary antibodies used were goat anti–rabbit Alexa 488 Green
and Alexa 594 Red (Cambridge Biosciences). Images were acquired on a
Zeiss LSM510 META confocal microscope (63  1.4NA plan-apochromat
oil immersion) at room temperature using Zeiss LSM510 v3.2 software;
Adobe Photoshop 6.0 (Adobe Systems, Inc.) was used for subsequent
image processing.
Inositol phosphate measurements
IP1-2 were assayed as described previously (Harnett and Harnett, 1993).
COS-7 cells were labeled with myo-[
3H]inositol (1  Ci/10
6 cells) for 24 h,
stimulated, and then subjected to chloroform/methanol (1:2) extraction fol-
lowed by Bligh-Dyer phase separation. Levels of IP1-2 were determined by
liquid scintillation counting of fractions eluted following Dowex (formate
form) ion exchange chromatography of aliquots of the aqueous phase. Re-
sults were calculated as a percentage of total incorporated radioactivity.
Levels of inositol-1,4,5-trisphosphate [IP3(1,4,5)] were measured in per-
chloric acid extracted samples (10
7 cells/aliquot) using the [
3H] Biotrak
Assay System (GE Healthcare) according to the manufacturer’s instructions.
Data are presented as mean   SD of triplicate measurements and are rep-
resentative of at least three separate experiments.
Statistical analysis
Pooled estimates for the changes in aggregate formation or cell death, re-
sulting from perturbations assessed in multiple experiments, were calcu-
lated as odds ratios with 95% confidence intervals. We have used this
method frequently in the past to allow analysis of data from multiple inde-
pendent experiments (Wyttenbach et al., 2001, 2002; Carmichael et al.,
2002). Odds ratios and P values were determined by unconditional logis-
tical regression analysis, using the general log-linear analysis option of
SPSS 9 software. Densitometry analysis was done by Scion Image Beta
4.02 software on immunoblots from three independent experiments. Sig-
nificance for clearance of mutant proteins was determined by factorial
ANOVA test using STATVIEW software, version 4.53 (Abacus Concepts)
and the error bar denotes standard error of the mean.
Online supplemental material
Fig. S1 shows lithium facilitated clearance of mutant huntingtin aggre-
gates, an effect not seen with NaCl. Fig. S2 shows lithium-induced autoph-
agy to facilitate clearance of mutant proteins. Fig. S3 shows a schematic
diagram of some molecular targets of lithium. Fig. S4 shows aspects of the
inositol cycle pertinent to lithium. Fig. S5 shows the mTOR pathway in re-
lation to autophagy. Online supplemental material available at http://
www.jcb.org/cgi/content/full/jcb.200504035/DC1.
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